Immunic, Inc. (NASDAQ:IMUX – Get Free Report) has received a consensus rating of “Buy” from the nine brokerages that are ...

Immunic, Inc. to Participate in Scientific and Industry Conferences in April ...

Fintel reports that on March 25, 2025, William Blair initiated coverage of Immunic (NasdaqGS:IMUX) with a Outperform ...

Immunic (IMUX – Research Report) received a Buy rating and a $1.20 price target from William Blair analyst Matt Phipps yesterday. The company’s ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today ...

In a challenging market environment, Immunic, Inc. (NASDAQ:IMUX) stock has recorded a new 52-week low, dipping to $0.92. The biopharmaceutical company, which focuses on developing treatments for ...

Analysts at William Blair issued their FY2026 EPS estimates for shares of Immunic in a research note issued to investors on ...

Short interest in Immunic Inc (NASDAQ:IMUX) decreased during the last reporting period, falling from 2.55M to 2.40M. This put 2.69% of the company's publicly available shares short. Short interest ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...